Open AccessCYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells
Author(s) -
János Kósa,
Péter Horváth,
János Wölfling,
Dóra Kovács,
Bernadett Ballá,
Péter Mátyus,
E Horváth,
Gábor Szabó,
István Takács,
Zsolt Nagy,
Hajnalka Horváth,
Péter L. Lakatos
Publication year - 2013
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v19.i17.2621
Subject(s) - cyp24a1 , sulforhodamine b , calcitriol , colorectal cancer , thymidylate synthase , vitamin d and neurology , viability assay , calcitriol receptor , vitamin , chemistry , cancer research , microbiology and biotechnology , pharmacology , biology , cell , medicine , cytotoxicity , cancer , biochemistry , fluorouracil , in vitro
The effects of vitamin D3 have been investigated on various tumors, including colorectal cancer (CRC). 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), the enzyme that inactivates the active vitamin D3 metabolite 1,25-dihydroxyvitamin D3 (1,25-D3), is considered to be the main enzyme determining the biological half-life of 1,25-D3. During colorectal carcinogenesis, the expression and concentration of CYP24A1 increases significantly, suggesting that this phenomenon could be responsible for the proposed efficacy of 1,25-D3 in the treatment of CRC. The aim of this study was to investigate the anti-tumor effects of vitamin D3 on the human CRC cell line Caco-2 after inhibition of the cytochrome P450 component of CYP24A1 activity.